Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
February 7, 2023
Assignees:
GALVANI BIOELECTRONICS LIMITED, TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY
Inventors:
Hans Jakob Kristoffer Famm, Harumi Hotta, Arun Sridhar
Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).
Type:
Application
Filed:
November 10, 2017
Publication date:
August 29, 2019
Applicants:
Galvani Bioelectronics Limited, Tokyo Metropolitan Institute of Gerontology
Inventors:
Hans Jakob Kristoffer FAMM, Harumi HOTTA, Arun SRIDHAR
Abstract: A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.
Type:
Grant
Filed:
June 29, 2001
Date of Patent:
October 18, 2011
Assignees:
Tokyo Metropolitan Institute of Gerontology, Chugai Seiyaku Kabushiki Kaisha